ArticleFrontiers in endocrinology2025
Real-World effectiveness of eculizumab in atypical hemolytic uremic syndrome: a retrospective study from Western China.
Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To evaluate the real-world efficacy and safety of eculizumab in atypical hemolytic uremic syndrome (aHUS) within a Western Chinese cohort, with emphasis on treatment initiation timing and renal outcomes. Methods: We conducted a retrospective analysis of 17 aHUS patients treated at Sichuan Provincial People's Hospital, focusing on the relationship between treatment timing and clinical prognosis. To evaluate timing effects, patients were categorized as Early Initiators (treatment within 7 days of symptom onset, n=9) versus Delayed Initiators (treatment beyond 7 days, n=8) The main outcome measures included hematological parameters, renal function, and adverse events. Results: The cohort (n=17, 76.5% female, mean age 43.2 ± 20.0 years) demonstrated significant improvements post-eculizumab: creatinine decreased from 647.0 (439.0, 915.0) to 198.5 (86.5, 749.5) μmol/L, eGFR increased from 8.0 (5.0, 11.0) to 22.1 (6.4, 55.1) mL/min/1.73m², platelets rose from 75 ± 11 to 143 ± 33×10 Conclusion: Our findings provide the first Chinese evidence supporting early eculizumab initiation (≤7 days post-symptom onset) significantly improves hematological/renal outcomes and reduces dialysis dependence in Chinese aHUS patients. Despite residual renal impairment, prompt complement blockade mitigates ESRD risk, supporting time-sensitive intervention in resource-limited settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.